Enzo Biochem Total Assets 2006-2021 | ENZ

Enzo Biochem total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Enzo Biochem Annual Total Assets
(Millions of US $)
2021 $114
2020 $113
2019 $107
2018 $102
2017 $108
2016 $112
2015 $68
2014 $64
2013 $59
2012 $69
2011 $109
2010 $115
2009 $133
2008 $155
2007 $159
2006 $102
2005 $116
Enzo Biochem Quarterly Total Assets
(Millions of US $)
2021-10-31 $108
2021-07-31 $114
2021-04-30 $114
2021-01-31 $112
2020-10-31 $114
2020-07-31 $113
2020-04-30 $116
2020-01-31 $117
2019-10-31 $125
2019-07-31 $107
2019-04-30 $111
2019-01-31 $89
2018-10-31 $94
2018-07-31 $102
2018-04-30 $105
2018-01-31 $108
2017-10-31 $109
2017-07-31 $108
2017-04-30 $107
2017-01-31 $106
2016-10-31 $110
2016-07-31 $112
2016-04-30 $76
2016-01-31 $81
2015-10-31 $74
2015-07-31 $68
2015-04-30 $59
2015-01-31 $60
2014-10-31 $63
2014-07-31 $64
2014-04-30 $63
2014-01-31 $56
2013-10-31 $58
2013-07-31 $59
2013-04-30 $58
2013-01-31 $62
2012-10-31 $67
2012-07-31 $69
2012-04-30 $96
2012-01-31 $99
2011-10-31 $104
2011-07-31 $109
2011-04-30 $110
2011-01-31 $111
2010-10-31 $115
2010-07-31 $115
2010-04-30 $116
2010-01-31 $127
2009-10-31 $132
2009-07-31 $133
2009-04-30 $138
2009-01-31 $140
2008-10-31 $147
2008-07-31 $155
2008-04-30 $151
2008-01-31 $151
2007-10-31 $157
2007-07-31 $159
2007-04-30 $154
2007-01-31 $141
2006-10-31 $103
2006-07-31 $102
2006-04-30 $106
2006-01-31 $107
2005-10-31 $112
2005-07-31 $116
2005-04-30 $116
2005-01-31 $118
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.160B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00